Literature DB >> 18573776

Estimating mean sojourn time and screening sensitivity using questionnaire data on time since previous screening.

Harald Weedon-Fekjaer1, Bo H Lindqvist, Lars J Vatten, Odd O Aalen, Steinar Tretli.   

Abstract

OBJECTIVES: Mean sojourn time (MST) and screening test sensitivity (STS), is usually estimated by Markov models using incidence data from the first screening round and the interval between screening examinations. However, several screening programmes do not have full registration of cancers submerging after screening, and increased use of opportunistic screening over time can raise questions regarding the quality of interval cancer registration. Methods/settings Based on the earlier used Markov model, formulas for expected number of cases given time since former screening activity was developed. Using questionnaire data for 336,533 women in the Norwegian Breast Cancer Screening Programme (NBCSP), mean square regression estimates of MST and STS were calculated.
RESULTS: In contrast to the previously used method, the new approach gave satisfactory model fit. MST was estimated to 5.6 years for women aged 50-59 years, and 6.9 years for women aged 60-69 years, and STS was estimated to 55% and 60%, respectively. Attempts to add separate parameters for breast cancer incidence without screening, or previous STS, resulted in wide confidence intervals if estimated separately, and non-identifiably if combined.
CONCLUSION: Previously published results of long MST and low screen test sensitivity were confirmed with the new approach. Questionnaire data on time since previous screening can be used to estimate MST and STS, but the approach is sensitive to relaxing the assumptions regarding the expected breast cancer incidence without screening and constant STS over time.

Entities:  

Mesh:

Year:  2008        PMID: 18573776     DOI: 10.1258/jms.2008.007071

Source DB:  PubMed          Journal:  J Med Screen        ISSN: 0969-1413            Impact factor:   2.136


  7 in total

1.  A Bayesian model for estimating multi-state disease progression.

Authors:  Shiwen Shen; Simon X Han; Panayiotis Petousis; Robert E Weiss; Frank Meng; Alex A T Bui; William Hsu
Journal:  Comput Biol Med       Date:  2016-12-22       Impact factor: 4.589

2.  Understanding recent trends in incidence of invasive breast cancer in Norway: age-period-cohort analysis based on registry data on mammography screening and hormone treatment use.

Authors:  Harald Weedon-Fekjær; Kjersti Bakken; Lars J Vatten; Steinar Tretli
Journal:  BMJ       Date:  2012-01-30

3.  Noise-Driven Phenotypic Heterogeneity with Finite Correlation Time in Clonal Populations.

Authors:  UnJin Lee; John J Skinner; John Reinitz; Marsha Rich Rosner; Eun-Jin Kim
Journal:  PLoS One       Date:  2015-07-23       Impact factor: 3.240

4.  Adjusting the incidence increase when screening for statistical lead time will always give estimates of overdiagnosis close to zero.

Authors:  Per-Henrik Zahl
Journal:  Breast Cancer Res       Date:  2014-06-04       Impact factor: 6.466

5.  Parameter estimates for invasive breast cancer progression in the Canadian National Breast Screening Study.

Authors:  S Taghipour; D Banjevic; A B Miller; N Montgomery; A K S Jardine; B J Harvey
Journal:  Br J Cancer       Date:  2013-01-15       Impact factor: 7.640

6.  Overestimated lead times in cancer screening has led to substantial underestimation of overdiagnosis.

Authors:  P-H Zahl; K J Jørgensen; P C Gøtzsche
Journal:  Br J Cancer       Date:  2013-08-20       Impact factor: 7.640

7.  A new statistical method for curve group analysis of longitudinal gene expression data illustrated for breast cancer in the NOWAC postgenome cohort as a proof of principle.

Authors:  Eiliv Lund; Lars Holden; Hege Bøvelstad; Sandra Plancade; Nicolle Mode; Clara-Cecilie Günther; Gregory Nuel; Jean-Christophe Thalabard; Marit Holden
Journal:  BMC Med Res Methodol       Date:  2016-03-05       Impact factor: 4.615

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.